Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Capital Expenditures (2019 - 2020)

Cyclerion Therapeutics has reported Capital Expenditures over the past 2 years, most recently at $35000.0 for Q4 2020.

  • Quarterly results put Capital Expenditures at $35000.0 for Q4 2020, up 100.59% from a year ago — trailing twelve months through Dec 2022 was $1.5 million (up 1173.11% YoY), and the annual figure for FY2021 was $7000.0, down 99.54%.
  • Capital Expenditures for Q4 2020 was $35000.0 at Cyclerion Therapeutics, down from $1.5 million in the prior quarter.
  • Over the last five years, Capital Expenditures for CYCN hit a ceiling of $4.2 million in Q2 2019 and a floor of -$5.9 million in Q4 2019.